后腹腔镜肾癌根治术对于T2期肾癌的临床治疗价值探讨

Clinical value of retroperitoneal laparoscopic radical nephrectomy for treatment of stage T2 renal cell carcinoma

目的：探讨后腹腔镜肾癌根治术对于T2期肾癌的临床治疗价值。方法选取2010年1月～2011年1月期间在我院接受治疗的60例T2期肾癌患者，随机分为实验组与对照组。实验组以后腹腔镜肾癌根治术进行治疗；对照组以开放式肾癌根治术进行治疗。判定后腹腔镜肾癌根治术对于T2期肾癌的临床治疗价值。结果60例患者手术均得以顺利实施，其中，实验组患者的手术平均时长约为（130.2±20.5）min；术中平均失血量为（130.5±10.0）mL；术后平均住院时长为（6.5±3.5）d。术后1年随访，仅1例患者发生疾病复发情况，其他患者均恢复良好；对照组患者手术平均时长为（165.8±30.2）min；术中平均失血量为（175.5±12.2）ml；术后平均住院时长为（15.5±4.2）d。术后1年随访，6例患者发生疾病复发情况。两组数据差异显著，结果具有统计意义（P＜0.05）。结论后腹腔镜肾癌根治术具有较高的临床治疗价值，其手术耗时短、患者术中出血量少、术后住院时间短、复发率低，该手术法值得在临床上广泛推广，帮助更多的肾癌患者受益。

ObjectiveTo explore the clinical value of retroperitoneal laparoscopic radical nephrectomy for treatment of stage T2 renal cell carcinoma. Methods 60 patients with stage T2 renal cell carcinoma treated in our hospital from Jan 2010 to Jan 2011 were selected and randomly assigned to the experimental group and the control group. The experimental group received retroperitoneal laparoscopic radical nephrectomy while the control group received open radical nephrectomy to determine to the clinical value of retroperitoneal laparoscopic radical nephrectomy for treatment of stage T2 renal cell carcinoma. ResultsAll the 60 patients had successful surgery. As for the experimental group, the average operation duration was （130.2±20.5）min; the average blood loss was （130.5±10.0）ml; the average postoperative hospital stay was （6.5±3.5）d; only 1 patient had recurrence within 1 year after the surgery and all other patients had good recovery. As for the control group, the average operation duration was （165.8±30.2）min; the average blood loss was （175.5±12.2）mL; the average postoperative hospital stay was （15.5±4.2）d; 6 patients had recurrence within 1 year after the surgery. There was statistical difference between the two groups.Conclusion Retroperitoneal laparoscopic radical nephrectomy has high value in clinical treatment with short operation duration, little blood loss, short postoperative hospital stay and low recurrence rate. The surgery is worthy of wide clinical promotion to benefit more patients with renal cell carcinoma.